Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

Biochemical Pharmacology

Volumn 64, Issue 7, 2002, Pages 1079-1090

  Sasakawa, Yuka ^a   Naoe, Yoshinori ^a   Inoue, Takeshi ^a   Sasakawa, Tatsuya ^a   Matsuo, Masahiko ^a   Manda, Toshitaka ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

FK228; Histone deacetylase inhibitor; Lymphoma; U 937

Indexed keywords

CD11 ANTIGEN; CD14 ANTIGEN; FR 901228; GELSOLIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN P21;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LYMPHOMA; LYMPHOMA CELL LINE; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SCID MOUSE; SURVIVAL TIME;

ACETYLATION; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CHOLECALCIFEROL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DEPSIPEPTIDES; DISEASE MODELS, ANIMAL; GELSOLIN; HISTONE DEACETYLASES; HISTONES; HUMANS; LEUKEMIA; LYMPHOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PEPTIDES, CYCLIC; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRETINOIN; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036775301     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01261-3     Document Type: Article

References (59)

1. Ueda H., Nakajima H., Hori Y., Fujita T., Nishimura M., Goto T., Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chomobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo). 47:1994;301-310.
2. Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I., Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chomobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo). 47:1994;315-323.
3. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241:1998;126-133.
4. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
5. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959.
6. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 384:1996;641-643.
7. Lee D.Y., Hayes J.J., Pruss D., Wolffe A.P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 72:1993;73-84.
8. Kingston R.E., Bunker C.A., Imbalzano A.N. Repression and activation by multiprotein complexes that alter chromatin structure. Genes Dev. 10:1996;905-920.
9. Ura K., Kurumizaka H., Dimitrov S., Almouzni G., Wolffe A.P. Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression. EMBO J. 16:1997;2096-2107.
10. Guidez F., Huang W., Tong J.-H., Dubois C., Balitrand N., Waxman S., Michaux J.L., Martiat P., Degos L., Chen Z., Chomienne C. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RARα patient. Leukemia. 8:1994;312-317.
11. David G., Alland L., Hong S.H., Wong C.W., DePinho R.A., Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene. 16:1998;2549-2556.
12. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H. Jr., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391:1998;811-814.
13. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., Seiser C., Grignani F., Lazar M.A., Minucci S., Pelicci P.G. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:1998;815-818.
14. He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P.P. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat. Genet. 18:1998;126-135.
15. Kitamura K., Hoshi S., Koike M., Kiyoi H., Saito H., Naoe T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol. 108:2000;696-702.
16. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., Tanimoto M., Murate T., Kawashima K., Saito H., Naoe T. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 13:1999;1316-1324.
17. Calabresse C., Venturini L., Ronco G., Villa P., Chomienne C., Belpomme D. Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line. Biochem. Biophys. Res. Commun. 195:1993;31-38.
18. Yen A., Brown D., Fishbaugh J. Control of HL-60 monocytic differentiation. Different pathways and uncoupled expression of differentiation markers. Exp. Cell Res. 168:1987;247-254.
19. Higgins P.J., Ryan M.P. p52(PAI-1) and actin expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells. Biochem. J. 279:1991;883-890.
20. Hoshikawa Y., Kwon H.J., Yoshida M., Horinouchi S., Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res. 214:1994;189-197.
21. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U.S.A. 96:1999;4592-4597.
22. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10014-10019.
23. Piekarz R.L., Robey R., Sandor V., Bakke S., Wilson W.H., Dahmoush L., Kingma D.M., Turner M.L., Altemus R., Bates S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 98:2001;2865-2868.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
25. Paine-Murrieta G.D., Taylor C.W., Curtis R.A., Lopez M.H., Dorr R.T., Johnson C.S., Funk C.Y., Thompson F., Hersh E.M. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother. Pharmacol. 40:1997;209-214.
26. Honma Y., Matsuo Y., Hayashi Y., Omura S. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor. Int. J. Cancer. 60:1995;685-688.
27. Kawata A., Yoshida M., Okazaki M., Yokota S., Barcos M., Seon B.K. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Cancer Res. 54:1994;2688-2694.
28. Ueda H., Nakajima H., Hori Y., Goto T., Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 58:1994;1579-1583.
29. Rajgolikar G., Chan K.K., Wang H.C. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. 51:1998;29-38.
30. Dimberg A., Nilsson K., Oberg F. Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood. 96:2000;2870-2878.
31. James S.Y., Williams M.A., Kelsey S.M., Newland A.C., Colston K.W. The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. Biochem. Pharmacol. 54:1997;625-634.
32. Ishii T., Moriyoshi K., Sugihara H., Sakurada K., Kadotani H., Yokoi M., Akazawa C., Shigemoto R., Mizuno N., Masu M., Nakanishi S. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J. Biol. Chem. 268:1993;2836-2843.
33. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell Biol. 18:1998;629-643.
34. Huang L., Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6:2000;849-866.
35. Futamura M., Monden Y., Okabe T., Fujita-Yoshigaki J., Yokoyama S., Nishimura S. Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells. Oncogene. 10:1995;1119-1123.
36. Cip1 in muscle and other terminally differentiating cells. Science. 267:1995;1024-1027.
37. Zhang W., Grasso L., McClain C.D., Gambel A.M., Cha Y., Travali S., Deisseroth A.B., Mercer W.E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 55:1995;668-674.
38. Carlos T.M., Harlan J.M. Membrane proteins involved in phagocyte adherence to endothelium. Immunol. Rev. 114:1990;5-28.
39. Perussia B., Lebman D., Ip S.H., Rovera G., Trinchieri G. Terminal differentiation surface antigens of myelomonocytic cells are expressed in human promyelocytic leukemia cells (HL60) treated with chemical inducers. Blood. 58:1981;836-843.
40. Dimitriu-Bona A., Burmester G.R., Waters S.J., Winchester R.J. Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J. Immunol. 130:1983;145-152.
41. Botling J., Öberg F., Törmä H., Tuohimaa P., Bläuer M., Nilsson K. Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Cell Growth Differ. 7:1996;1239-1249.
42. Ferrara F.F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P.G., Lo Coco F., Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61:2001;2-7.
43. Witt O., Sand K., Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 95:2000;2391-2396.
44. Passmore J.S., Lukey P.T., Ress S.R. The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen-specific cytotoxic T-cell function. Immunology. 102:2001;146-156.
45. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241:1997;142-150.
46. Nakano K., Mizuno T., Sowa Y., Orita T., Yoshino T., Okuyama Y., Fujita T., Ohtani-Fujita N., Matsukawa Y., Tokino T., Yamagishi H., Oka T., Nomura H., Sakai T. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem. 272:1997;22199-22206.
47. WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene. 19:2000;5712-5719.
48. waf1 transcription in human cells. J. Biol. Chem. 275:2000;30725-30733.
49. Doetzlhofer A., Rotheneder H., Lagger G., Koranda M., Kurtev V., Brosch G., Wintersberger E., Seiser C. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol. Cell Biol. 19:1999;5504-5511.
50. waf1/cip1 promoter activation induced by histone deacetylase inhibitor. J. Biol. Chem. 275:2000;1371-1376.
51. Sowa Y., Orita T., Minamikawa-Hiranabe S., Mizuno T., Nomura H., Sakai T. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res. 59:1999;4266-4270.
52. WAF promoter. Biochem. Biophys. Res. Commun. 256:1999;249-254.
53. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., Xu H., Cohen D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274:1999;34940-34947.
54. Zhou X., Marks P.A., Rifkind R.A., Richon V.M. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10572-10577.
55. Miller T.P., Dahlberg S., Cassady J.R., Adelstein D.J., Spier C.M., Grogan T.M., LeBlanc M., Carlin S., Chase E., Fisher R.I. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 339:1998;21-26.
56. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., Glick J.H., Coltman C.A. Jr., Miller T.P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328:1993;1002-1006.
57. Smalley R.V., Andersen J.W., Hawkins M.J., Bhide V., O'Connell M.J., Oken M.M., Borden E.C. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N. Engl. J. Med. 327:1992;1336-1341.
58. Solal-Celigny P., Lepage E., Brousse N., Reyes F., Haioun C., Leporrier M., Peuchmaur M., Bosly A., Parlier Y., Brice P., Coiffier B. Gisselbrecht C for the groupe d'etude des lymphomes de l'Adulte. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N. Engl. J. Med. 329:1993;1608-1614.
59. Fisher R.I., Dana B.W., LeBlanc M., Kjeldsberg C., Forman J.D., Unger J.M., Balcerzak S.P., Gaynor E.R., Roy V., Miller T. Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group Randomized Phase III Study 8809. J. Clin. Oncol. 18:2000;2010-2016.